

New shares from the exercise of Prostatype Genomics AB's warrants of series TO 4 is now registered at the Swedish Companies Registration Office

Prostatype Genomics AB ("Prostatype" or "Company") today announces that the new shares from the exercise of the Company's warrants of series TO 4 ("TO 4") have been registered with the Swedish Companies Registration Office. Conversion from interim shares to ordinary shares will take place on 27 December 2024, and the first day of trading for the new shares is expected on 2 January 2025.

Registration of shares

The exercise period for Prostatype's warrants of series TO 4 which were issued in connection with the Company's rights issue of units and subsequent directed issue to guarantors in August 2024, ended on 9 December 2024. Outcome of the TO 4 exercise were that 1,556,419,000 warrants were exercised for the subscription of 1,556,419 new shares. The new shares are now registered with the Swedish Companies Registration Office, and an application to convert interim shares into ordinary shares have been submitted to Euroclear.

The conversion from interim shares to ordinary shares will take place around 27 December 2024, and the new shares are expected to be available in the respective subscribers' accounts around 2 January 2025.

Number of shares and share capital

After registration of the new share from the TO 4 exercise, the number of shares in the Company is now 6,704,770 shares, and the Company's share capital amounts to 670,477 SEK.

Directed Issue to guarantors of TO 4 exercise

The board of directors in Prostatype intends to carry out a directed issue to guarantors of the TO 4 exercise, which will further increase the number of shares and the share capital in the Company. For more information about the directed issue, see the press release issued by the Company on 10 December 2024.

Advisors

In connection with the TO 4 exercise, Prostatype engaged Gemstone Capital ApS as financial advisor, Advokatfirman Lindahl KB as legal advisor and Nordic Issuing AB as issuing agent.

For more information about the Company, please contact:

Fredrik Rickman, CEO

Tel: +46 (0)73-049 77 01

E-mail: fredrik.rickman@prostatypegenomics.com

Certified Advisors

Carnegie Investment Bank AB (publ), +46 73 856 42 65, certifiedadviser@carnegie.se

About Prostatype

Prostatype® is a genetic test that is available to patients and treating urologists as a complementary decision support tool to answer the question of radical treatment or no radical treatment of prostate cancer. The test was developed by a leading research group at Karolinska Institutet and is provided by Prostatype Genomics AB.